公开(公告)号：US20150342951A1

公开(公告)日：2015-12-03

申请号：US14365512

申请日：2012-12-14

Applicant: NOVARTIS AG

Inventor： Nigel Graham COOKE ,  Paulo Antonio FERNANDES GOMES DOS SANTOS ,  Pascal FURET ,  Christina HEBACH ,  Klemens HOGENAUER ,  Gregory HOLLINGWORTH ,  Christoph KALIS ,  Ian LEWIS ,  Alexander Baxter SMITH ,  Nicolas SOLDERMANN ,  Frederic STAUFFER ,  Ross STRANG ,  Frank STOWASSER ,  Nicola TUFFILLI ,  Anette VON MATT ,  Romain WOLF ,  Frederic ZECRI

IPC: A61K31/519 ,  A61K31/551 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/517

CPC classification number: A61K31/519 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  C07D239/74 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D487/08 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414

Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Abstract translation: 本发明涉及PI3K抑制剂的新用途，其中所述抑制剂对PI3K同种型δ具有抑制作用，用于治疗患有选自疟疾，利什曼病，锥虫病，弓形虫病和/或神经囊尾erc病的疾病或病症的受试者的免疫病理学， 通过功能抑制受感染受试者的TLR9。